Skip to main content
GenSight Biologics S.A. logo

GenSight Biologics S.A. — Investor Relations & Filings

Ticker · SIGHT ISIN · FR0013183985 LEI · 549300NK4AB8OUEX1F54 PA Manufacturing
Open in API
Filings indexed 627 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country FR France
Listing PA SIGHT

About GenSight Biologics S.A.

https://www.gensight-biologics.com

GenSight Biologics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for patients with neurodegenerative retinal diseases and disorders of the central nervous system. The company's therapeutic approach is based on two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics. Its lead product candidate, LUMEVOQ (lenadogene nolparvovec), is a gene therapy in late-stage clinical development for treating vision loss from rare mitochondrial diseases. The company's pipeline also includes GS030, an optogenetic-based therapy in clinical trials for retinal degenerative diseases.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release announcing the outcomes of shareholders’ votes at the Combined General Meeting held on May 19, 2026. It lists the approved resolutions and refers to the vote results, fitting the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-20 English
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 89% confidence The document is a press release announcing the results of the company’s Annual General Meeting held on May 19, 2026, listing the resolutions approved and referring to the vote tally. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (Code: DVA).
2026-05-20 French
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information
2026-05-18 French
Terms of availability of the preparatory documents for the GM
AGM Information
2026-05-18 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 12% confidence The document is a press release announcing the publication of a scientific article (matching-adjusted indirect comparison) in a medical journal. It does not contain any financial statements, regulatory compliance details, management changes, dividends, or meeting materials. It is not a company report itself, nor an announcement of a financial or corporate report; it is simply a publicity announcement of an academic publication. No specific category (e.g., Annual Report, Interim Report, Earnings Release, Dividend Notice, etc.) applies. Therefore, we classify it into the fallback category for miscellaneous regulatory/other announcements: Regulatory Filings (RNS).
2026-05-11 French
Inside Information / Other news releases
Regulatory Filings Classification · 12% confidence The document is a corporate press release announcing the publication of a clinical trial comparison in a scientific journal. It does not contain financial results, governance changes, shareholder actions, or detailed report data. It is not an investor presentation or report attachment notice for an annual or interim report. Therefore, it falls into the general regulatory/press release fallback category.
2026-05-11 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.